Cornea

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

The novel therapeutic for keratoconus does not require corneal epithelium removal and is slated to launch commercially in early 2026.

Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported

Highlights from the 2025 Heidelberg Engineering International SPECTRALIS Symposium—And Beyond

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

The investigational device, ETX-4143, was the focus of a study involving 31 patients with COSP in Australia

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

A five-step approach to personalise and simplify treatment, leading to higher efficacy

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

AURN001 is Aurion Biotech's clinical-stage allogeneic cell therapy asset for corneal oedema secondary to corneal endothelial disease

The authors examined vascular and neural structures in the eye, assessing the foveal avascular zone and choroidal thickness

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set

Prophylactic cyclosporine A 0.1% eye drops were associated with improved ocular surface homeostasis and reduced inflammation

A large-scale study indicates women are more likely to develop the inherited corneal condition

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

The authors said their results provide strong support that cultivated autologous limbal epithelial cell transplantation is safe and feasible

The authors emphasised that consumers and clinicians should be made aware of potential ophthalmic adverse events associated with cosmetics and personal care products

A qualitative study method illuminates patients’ fears for the future

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

Highlights from the year, courtesy of our colleagues at Ophthalmology Times